TYRUKO

This brand name is authorized in Austria, Croatia, Estonia, France, Ireland, Italy, Lithuania, Spain, UK.

Active ingredients

The drug TYRUKO contains one active pharmaceutical ingredient (API):

1	Natalizumab UNII 3JB47N2Q2P - NATALIZUMAB
	Natalizumab is a selective adhesion-molecule inhibitor and binds to the α4-subunit of human integrins, which is highly expressed on the surface of all leukocytes, with the exception of neutrophils.
	Read more about Natalizumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
TYRUKO Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L04AG03	Natalizumab	L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AG Monoclonal antibodies
Discover more medicines within L04AG03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3047734
ES	Centro de información online de medicamentos de la AEMPS	1231745001
FR	Base de données publique des médicaments	60779570
IT	Agenzia del Farmaco	050762018
LT	Valstybinė vaistų kontrolės tarnyba	1097837